Medtronic's much-scrutinized Infuse spinal implant performs no better than traditional bone grafts and carries an increased risk of cancer, sterility and other side effects, according to two independent reviews.
Some observers were predicting defeat. But in German court, at least, Medtronic came out ahead in its heart pump patent battle with Edwards Lifesciences.
Massachusetts' MC10 has developed a stretchable, sensor-laden technology you can wear, allowing for vital readings on the go, and with big-name backers like Medtronic and Reebok, the company believes its innovation could revolutionize mobile health.
The FDA jumped off the sidelines in the ongoing discussion about threats to networked medical devices, issuing draft guidance to manufacturers and others to take additional precautions against cyberattacks that endanger patients.
Medtronic is debuting a new surgical tool in Europe designed to help surgeons perform osteotomies to treat severe spinal curvature in adults. The launch comes in tandem with a new CE mark.
Medtronic may be at risk of losing big in a patent battle with one company, but the Minnesota device giant is on the winning side of another dustup with a different rival, at least for now.
Expect Edwards Lifesciences' aggressive and increasingly hard-core heart valve patent battle with Medtronic to get worse in the coming weeks. An industry analyst predicts that a German court will issue an injunction preventing Medtronic from selling its CoreValve transcatheter aortic valve replacement in that country. And continued legal action is advancing in the U.S.
A year after Johnson & Johnson snatched up Swiss orthopedic devicemaker Synthes for an astounding $21.3 billion, the merging of operations is incredibly slow-going and has cost the combined company some business and research talent, the Swiss publication Finanz und Wirtschaft ( Finance and Economics ) reports.
C.R. Bard is working hard to show the versatility of its Lutonix drug-coated balloon, even before it wins FDA approval. A few years after acquiring the technology in a $225 million grab of a company with the same name, the first human patient has joined a new trial testing the device below the knee.
Medtronic is expanding its presence in peripheral artery disease, winning FDA clearance and a CE mark for the Pacific Plus balloon catheter, a next-generation vascular treatment.